{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:42:18Z","timestamp":1791380538258,"version":"4.3.3"},"reference-count":62,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Background\nThe impact of menopause is a consequence of social, physical and mental changes; hormonal changes play an important role in inducing an increased risk of developing depressive symptoms. It is essential to treat mood and vasomotor symptoms and to prevent their onset to promote an improvement in the quality of life, both in terms of clinical and psychological conditions.\nObjective\nThis observational study aims to compare paroxetine and vortioxetine in a sample of patients affected by postmenopausal depression attending the Anxiety and Depression Clinic in terms of: efficacy in determining clinical remission (HDRS \u2264 7) and tolerability; improvement of autonomic and cognitive symptoms.\nMethods\n39 female outpatients with a diagnosis of Postmenopausal Depression (according to DSM-5 criteria) were evaluated as the routine clinical practice through the following scales: Hamilton Depression Rating Scale (HDRS); Menopause Rating Scale (MRS); Montreal Cognitive Assessment (MoCA); Antidepressant Side-Effect Checklist (ASEC); data from\/of baseline, after 8 weeks and 12 weeks were recorded.\nResults\nBoth antidepressants resulted to be effective in clinical remission (HDRS \u2264 7) without statistical differences between the two groups (p = 0.3), although paroxetine showed a faster remission than vortioxetine (p = 0.01). Autonomic symptoms showed a higher improvement in the vortioxetine group (p = 0.002). Paroxetine group referred insomnia and sexual problems while patients taking vortioxetine referred diarrhoea and palpitations. Data show a superiority of cognitive performance in the Paroxetine group (p = 0.005), contrary to what stated in literature.\nConclusions\nData are related to a small sample retrospectively assessed trough a 6-month observation period. Thus, the preliminary results need further research to be confirmed.<\/jats:p>","DOI":"10.64719\/pb.4586","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"28-43","source":"Crossref","is-referenced-by-count":3,"title":["Paroxetine versus Vortioxetine for Depressive Symptoms in Postmenopausal Transition: A Preliminary Study"],"prefix":"10.64719","volume":"49","author":[{"given":"Camilla","family":"Callegari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ielmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Caselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Isella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Diurni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Pettenon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Poloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Callegari C, Buttarelli M, Cromi A, Diurni M, Salvaggio F, Bolis PF. Female psychopathologic profile during menopausal transition: a preliminary study. Maturitas. 2007;56(4):447\u2013451.","DOI":"10.1016\/j.maturitas.2006.08.001"},{"key":"ref2","unstructured":"Callegari C, Buttarelli M, Cromi A, Diurni M, Salvaggio F, Bolis PF. Incidence of depressive symptoms in women attending a menopause clinic: A preliminary study [Incidenza di sintomatologia depressive in donne in cura presso una clinica per la menopausa: uno studio preliminare] Minerva Psichiatrica. 2007;48(1):11\u201319."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Borkoles E, Reynolds N, Thompson DR, Ski CF, Stojanovska L, Polman RC. The role of depressive symptomatology in peri- and post-menopause. Maturitas. 2015;81(2):306\u2013310.","DOI":"10.1016\/j.maturitas.2015.03.007"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Brown L, Bryant C, Brown VM, Bei B, Judd FK. Self-compassion weakens the association between hot flushes and night sweats and daily life functioning and depression. Maturitas. 2014;78(4):298\u2013303.","DOI":"10.1016\/j.maturitas.2014.05.012"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Nappi RE, Albani F, Santamaria V, Tonani S, Magri F, Martini E, Chiovato L, Polatti F. Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas. 2010;67(1):78\u201383.","DOI":"10.1016\/j.maturitas.2010.05.008"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"de Kruif M, Spijker AT, Molendijk ML. Depression during the perimenopause: A meta-analysis. J Affect Disord. 2016;206:174\u2013180.","DOI":"10.1016\/j.jad.2016.07.040"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Mulhall S, Andel R, Anstey KJ. Variation in symptoms of depression and anxiety in midlife women by menopausal status. Maturitas. 2018;108:7\u201312.","DOI":"10.1016\/j.maturitas.2017.11.005"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Freeman EW, Sammel MD, Boorman DW, Zhang R. Longitudinal pattern of depressive symptoms around natural menopause. JAMA Psychiatry. 2014;71(1):36\u201343.","DOI":"10.1001\/jamapsychiatry.2013.2819"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Jung SJ, Shin A, Kang D. Menarche age, menopause age and other reproductive factors in association with post-menopausal onset depression: Results from Health Examinees Study (HEXA) J Affect Disord. 2015;187:127\u2013135.","DOI":"10.1016\/j.jad.2015.08.047"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids. 2007;72(5):381\u2013405.","DOI":"10.1016\/j.steroids.2007.02.003"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Begliuomini S, Casarosa E, Pluchino N, Lenzi E, Centofanti M, Freschi L, Pieri M, Genazzani AD, Luisi S, Genazzani AR. Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod. 2007;22(4):995\u20131002.","DOI":"10.1093\/humrep\/del479"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol. 2008;29(4):507\u2013519.","DOI":"10.1016\/j.yfrne.2008.04.001"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Llaneza P, Garc\u00eda-Portilla MP, Llaneza-Su\u00e1rez D, Armott B, P\u00e9rez-L\u00f3pez FR. Depressive disorders and the menopause transition. Maturitas. 2012;71(2):120\u2013130.","DOI":"10.1016\/j.maturitas.2011.11.017"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Jung SJ, Shin A, Kang D. Hormone-related factors and post-menopausal onset depression: results from KNHANES (2010\u20132012) J Affect Disord. 2015;175:176\u2013183.","DOI":"10.1016\/j.jad.2014.12.061"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Birkh\u00e4user M. Depression, menopause and estrogens: is there a correlation? Maturitas. 2002;41(Suppl 1):S3\u2013S8.","DOI":"10.1016\/S0378-5122(02)00009-9"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63(4):375\u2013382.","DOI":"10.1001\/archpsyc.63.4.375"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Judd FK, Hickey M, Bryant C. Depression and midlife: are we overpathologising the menopause? J Affect Disord. 2012;136(3):199\u2013211.","DOI":"10.1016\/j.jad.2010.12.010"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Mulhall S, Andel R, Anstey KJ. Variation in symptoms of depression and anxiety in midlife women by menopausal status. Maturitas. 2018;108:7\u201312.","DOI":"10.1016\/j.maturitas.2017.11.005"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63(4):385\u2013390.","DOI":"10.1001\/archpsyc.63.4.385"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Clayton AH, Ninan PT. Depression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women. Prim Care Companion J Clin Psychiatry. 2010;12(1)","DOI":"10.4088\/PCC.08r00747blu"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Gibbs Z, Lee S, Kulkarni J. What factors determine whether a woman becomes depressed during the perimenopause? Arch Womens Ment Health. 2012;15(5):323\u2013332.","DOI":"10.1007\/s00737-012-0304-0"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Soares CN. Can depression be a menopause-associated risk? BMC Med. 2010;8:79.","DOI":"10.1186\/1741-7015-8-79"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Reed SD, Ludman EJ, Newton KM, Grothaus LC, LaCroix AZ, Nekhlyudov L, Spangler L, Jordan L, Ehrlich K, Bush T. Depressive symptoms and menopausal burden in the midlife. Maturitas. 2009;62(3):306\u2013310.","DOI":"10.1016\/j.maturitas.2009.01.002"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Worsley R, Bell R, Kulkarni J, Davis SR. The association between vasomotor symptoms and depression during perimenopause: a systematic review. Maturitas. 2014;77(2):111\u2013117.","DOI":"10.1016\/j.maturitas.2013.11.007"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Natari RB, Clavarino AM, McGuire TM, Dingle KD, Hollingworth SA. The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies. Menopause. 2018;25(1):109\u2013120.","DOI":"10.1097\/GME.0000000000000949"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Muharam R, Setiawan MW, Ikhsan M, Rizkinya HE, Sumapraja K. Depression and its link to other symptoms in menopausal transition. Middle East Fertil Soc J. 2018;23(1):27\u201330.","DOI":"10.1016\/j.mefs.2017.08.003"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Cuadros JL, Fern\u00e1ndez-Alonso AM, Cuadros-Celorrio AM, Fern\u00e1ndez-Luz\u00f3n N, Guadix-Peinado MJ, del Cid-Mart\u00edn N, Chedraui P, P\u00e9rez-L\u00f3pez FR. Perceived stress, insomnia and related factors in women around the menopause. Maturitas. 2012;72(4):367\u2013372.","DOI":"10.1016\/j.maturitas.2012.05.012"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Afshari P, Sedighe M, Mitra T, Mahbobeh K, Mohammadhosain H. Prevalence of Depression in Postmenopausal Women. Jundishapur J Chronic Dis Care. 2015;4(3)","DOI":"10.5812\/jjcdc.27521v2"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202\u2013216.","DOI":"10.1097\/01.AOG.0000441353.20693.78"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Pehrson AL, Leiser SC, Gulinello M, Dale E, Li Y, Waller JA, Sanchez C. Treatment of cognitive dysfunction in major depressive disorder \u2013 a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur J Pharmacol. 2015;753:19\u201331.","DOI":"10.1016\/j.ejphar.2014.07.044"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Davari-Tanha F, Soleymani-Farsani M, Asadi M, Shariat M, Shirazi M, Hadizadeh H. Comparison of citalopram and venlafaxine\u2019s role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. Arch Gynecol Obstet. 2016;293(5):1007\u20131013.","DOI":"10.1007\/s00404-015-3900-1"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Weber L, Thacker HL. Paroxetine: a first for selective serotonin reuptake inhibitors \u2013 a new use: approved for vasomotor symptoms in postmenopausal women. Womens Health (Lond) 2014;10(2):147\u2013154.","DOI":"10.2217\/WHE.14.3"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists. Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202\u2013216.","DOI":"10.1097\/01.AOG.0000441353.20693.78"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Carris N, Kutner S, Reilly-Rogers S. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene\/conjugated estrogens and paroxetine mesylate. Ann Pharmacother. 2014;48(10):1343\u20131349.","DOI":"10.1177\/1060028014543099"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Wei D, Chen Y, Wu C, Wu Q, Yao L, Wang Q, Wang XQ, Yang KH. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis. BJOG. 2016;123(11):1735\u20131743.","DOI":"10.1111\/1471-0528.13951"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ielmini M, Poloni N, Caselli I, Bianchi L, Diurni M, Vender S, Callegari C. Efficacy and Tolerability of Two Different Kinds of Titration of Paroxetine Hydrocloride Solution: an Observational Study. Psychopharmacol Bull. 2018;48(3):33\u201341.","DOI":"10.64719\/pb.4567"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Katona CL, Katona CP. New generation multi\u2013modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:349\u2013354.","DOI":"10.2147\/NDT.S39544"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"De Bartolomeis A, Fagiolini A, Maina G. Vortioxetina nel trattamento della depressione maggiore. Riv Psichiatr. 2016;51(6):215\u2013230.","DOI":"10.1708\/2596.26720"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr. 2017;22(4):348\u2013362.","DOI":"10.1017\/S1092852916000626"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short\u2013term, randomized, double-blind, exploratory study. J Affect Disord. 2018;229:421\u2013428.","DOI":"10.1016\/j.jad.2017.12.056"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. Journal of Affective Disorders. 2018;227:787\u2013794.","DOI":"10.1016\/j.jad.2017.11.081"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord. 2018;227:803\u2013809.","DOI":"10.1016\/j.jad.2017.11.053"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Freeman MP, Cheng LJ, Moustafa D, Davies A, Sosinsky AZ, Wang B, Petrillo LF, Hogan C, Cohen LS. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. Ann Clin Psychiatry. 2017;29(4):249\u2013257.","DOI":"10.1177\/104012371702900407"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Callegari C, Ielmini M, Bianchi L, Lucano M, Bert\u00f9 L, Vender S. Antiepileptic drug use in a nursing home setting: a retrospective study in older adults. Funct Neurol. 2016;31(2):87\u201393.","DOI":"10.11138\/FNeur\/2016.31.2.087"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Brignone M, Diamand F, Painchault C, Takyar S. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Curr Med Res Opin. 2016;32(2):351\u2013366.","DOI":"10.1185\/03007995.2015.1128404"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Connolly KR, Thase M. Vortioxetine: a New Treatment for Major Depressive Disorder. Expert Opin Pharmacother. 2016;17(3):421\u2013431.","DOI":"10.1517\/14656566.2016.1133588"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev. 2017;7 CD011520.","DOI":"10.1002\/14651858.CD011520.pub2"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Thase ME, Danchenko N, Brigone M, Florea I, Diamand F, Jacobsen PL, Vieta E. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Eur Neuropsychopharmacol. 2017;27(8):773\u2013781.","DOI":"10.1016\/j.euroneuro.2017.05.009"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Dell\u2019Osso B, Albert U, Atti AR, Carmassi C, Carr\u00e0 G, Cosci F, Del Vecchio V, Di Nicola M, Ferrari S, Goracci A, Iasevoli F, Luciano M, Martinotti G, Nanni MG, Nivoli A, Pinna F, Poloni N, Pompili M, Sampogna G, Tarricone I, Tosato S, Volpe U, Fiorillo A. Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat. 2015;11:1885\u20131909.","DOI":"10.2147\/NDT.S83130"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Albert U, Carmassi C, Cosci F, De Cori D, Di Nicola M, Ferrari S, Poloni N, Tarricone I, Fiorillo A. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016;31(5):249\u2013258.","DOI":"10.1097\/YIC.0000000000000127"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Diurni M, Baranzini F, Costantini C, Poloni N, Vender S, Callegari C. Metabolic side effects of second generation antipsychotics in drug-na\u00efve patients: a preliminary study. Riv Psichiatr. 2009;44(3):176\u2013178.","DOI":"10.1708\/438.5173"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta\u2013analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord. 2016;206:140\u2013150.","DOI":"10.1016\/j.jad.2016.07.015"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"De Bartolomeis A, Fagiolini A, Maina G. Vortioxetina nel trattamento della depressione maggiore. Riv Psichiatr. 2016;51(6):215\u2013230.","DOI":"10.1708\/2596.26720"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Cuadros JL, Fernandez-Alonso AM, Cuadros AM, Fernandez-Luz\u00f2n N, Guadix-Peinado MJ, del Cid-Mart\u00ecn N, Chedraui P, Perez-Lopez P. Perceived stress, insomnia and related factors in women around the menopause. Maturitas. 2012;72(4):367\u2013372.","DOI":"10.1016\/j.maturitas.2012.05.012"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"DiBonaventura MD, Wagner JS, Alvir J, Whiteley J. Depression, quality of life, work productivity, resource use, and costs among women experiencing menopause and hot flashes: a cross\u2013sectional study. Prim Care Companion CNS Disord. 2012;14(6)","DOI":"10.4088\/PCC.12m01410"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Cheng LJ, Choen LS, Davies A, Freeman MP, Hogan C, Moustafa D, Petrillo LF, Sosinsky AZ, Wang B. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. Ann Clin Psychiatry. 2017;29(4):249\u2013257.","DOI":"10.1177\/104012371702900407"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Singh AB. Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. Clin Psychopharmacol Neurosci. 2015;13(2):150\u2013156.","DOI":"10.9758\/cpn.2015.13.2.150"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Poloni N, Callegari C, Buzzi A, Aletti F, Baranzini F, Vecchi F, Vender S. The Italian version of ISOS and RSQ, two suitable scales for investigating recovery style from psychosis. Epidemiol Psichiatr Soc. 2010;19(4):352\u2013359.","DOI":"10.1017\/S1121189X00000695"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Poloni N, Diurni M, Buzzi A, Cazzamalli S, Aletti F, Baranzini F. Recovery style, symptoms and psychosocial functioning in psychotic patients: a preliminary study. Rivista di Psichiatria. 2013;48(5):386\u2013392.","DOI":"10.1708\/1356.15065"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Vender S, Poloni N, Aletti F, Bonalumi C, Callegari C. Service Engagement: Psychopathology, Recovery Style and Tratments. Psychiatry J. 2014 249852:6 pages.","DOI":"10.1155\/2014\/249852"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Callegari C, Bert\u00f9 L, Caselli I, Isella C, Ielmini M, Bonalumi C, Ferrario F, Vender S. Resilience in older adults: influence of the admission in nursing home and psychopathology. Neuropsychiatry (London) 2016;6(4):117\u2013123.","DOI":"10.4172\/Neuropsychiatry.1000129"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Callegari C, Bert\u00f9 L, Lucano M, Ielmini M, Braggio E, Vender S. Reliability and validity of the Italian version of the 14-item Resilience Scale. Psychol Res Behav Manag. 2016;3(9):277\u2013284.","DOI":"10.2147\/PRBM.S115657"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:34:57Z","timestamp":1791315297000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/paroxetine-versus-vortioxetine-for-depressive-symptoms-in-postmenopausal-transition-a-preliminary-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4586","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}